Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants
Part of paid clinical trials in Kansas City, Missouri.
- Sponsor
- OPKO Health, Inc.
- Study ID
- NCT07494045
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- CKD Stage 3
- CKD Stage 4
- Secondary Hyperparathyroidism
- VDI
Eligibility Criteria
- Sex
- ALL
- Age
- 1 Month - 17 Years
- Healthy Volunteers
- Not accepted
Interventions
- CTAP101 — DRUGCapsules
Study Details
The goal of this clinical trial is to evaluate safety, tolerability, and how CTAP101 Capsules work to treat Pediatric Participants with Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency. The main questions it aims to answer are: 1. To assess the pharmacokinetics (PK) and Pharmacodynamics (PD) of CTAP101 Capsules 2. To investigate the safety and tolerability of CTAP101 Capsules Participants will take a daily dosage of CTAP101 Capsules at bedtime for 8 weeks.
Key Dates
- First listed
- Mar 27, 2026
- Start date
- Aug 5, 2026
- Status verified
- Aug 2026
- Primary completion
- Oct 31, 2027
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Cohort 1 - Group A30 mcg CTAP101 Capsules
- Experimental: Cohort 1 - Group B30 mcg or 60 mcg CTAP101 Capsules
Primary Outcome Measure
Apparent clearance (CL/F) [ Time Frame: Up to 14 weeks ]
Central Contacts
- OPKO Health305-575-4100
Locations (5)
Find similar trials in Kansas City, MO
Related Studies
- A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPHASE3 · Recruiting · Amgen · Los Angeles, California
- Precision Medicine Approaches to Renal OsteodystrophyRecruiting · Thomas Nickolas · St Louis, Missouri
- Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same DonorPHASE1/PHASE2 · Recruiting · Alice Bertaina · Palo Alto, California
- Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney DiseaseEnrolling By Invitation · University of California, Irvine · Orange, California